US 12,296,043 B2
Liquisoft capsules
Yinyan Zhao, Greensboro, NC (US); Yunhua Hu, Cary, NC (US); Mervin Williams, Jr., Jamestown, NC (US); Tatyana Dyakonov, Greensboro, NC (US); Saujanya Gosangari, Jamestown, NC (US); Chue Yang, Greensboro, NC (US); Henricus Marinus Gerardus Maria Van Duijnhoven, den Bosch (NL); Martin Piest, Tilburg (NL); and Aqeel A. Fatmi, High Point, NC (US)
Assigned to Patheon Softgels Inc., High Point, NC (US)
Filed by PATHEON SOFTGELS INC., High Point, NC (US)
Filed on Nov. 30, 2023, as Appl. No. 18/524,738.
Application 18/524,738 is a continuation of application No. 17/704,306, filed on Mar. 25, 2022, granted, now 11,872,307.
Application 17/704,306 is a continuation of application No. 16/722,196, filed on Dec. 20, 2019, abandoned.
Application 16/722,196 is a continuation of application No. 15/795,814, filed on Oct. 27, 2017, granted, now 10,555,901, issued on Feb. 11, 2020.
Application 15/795,814 is a continuation of application No. 15/080,614, filed on Mar. 25, 2016, granted, now 9,867,779, issued on Jan. 16, 2018.
Claims priority of provisional application 62/236,297, filed on Oct. 2, 2015.
Claims priority of provisional application 62/138,468, filed on Mar. 26, 2015.
Prior Publication US 2024/0165020 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/56 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 31/045 (2006.01); A61K 31/485 (2006.01)
CPC A61K 9/0056 (2013.01) [A61K 9/4825 (2013.01); A61K 9/4833 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/045 (2013.01); A61K 31/485 (2013.01)] 9 Claims
 
1. A shell formulation for an oral pharmaceutical composition suitable for chewing, sucking, or buccal dissolution, the shell formulation comprising: (a) less than 35% by weight of the shell formulation of two or more gelatins, wherein hydrolyzed gelatin comprises about 15% by weight of the two or more gelatins;
(b) about 30% to about 70% by weight of the shell formulation of glycerol, maltitol, mannitol, xylitol, lycasin, or combinations thereof;
(c) about 0.25% to about 2% by weight of the shell formulation of citric acid, acetic acid, lactic acid, malic acid, tartaric acid, or combinations thereof;
(d) about 0.1% to about 5% by weight of the shell formulation of sucralose, aspartame, stevia, acesulfame potassium, xylitol, or combinations thereof; and
(e) about 10% to about 40% by weight of the shell formulation of water,
Wherein the shell formulation encapsulates a fill, the fill comprising:
about 20% to about 90% by weight of the fill of one or more lipids or lipophilic vehicles;
about 1% to about 20% by weight of the fill of one or more solvents;
and about 0.25% to about 50% by weight of the fill of one or more active pharmaceutical ingredients.